LILRB2 and melanoma: In the phase 1/2 KEYMAKER-U02 substudy 02C of neoadjuvant treatment followed by adjuvant pembrolizumab in patients with stage IIIB–D melanoma, the MPR rate was 50%, 40% and 32% with pembrolizumab plus vibostolimab (an anti-TIGIT antibody), gebasaxturev (an oncolytic enterovirus) and MK-4830 (an anti-ILT4 antibody), respectively; 58% with pembrolizumab co-formulated with favezelimab (an anti-LAG-3 antibody); and 47% with pembrolizumab monotherapy.